18:29 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Biomatics closes second fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase" ). Fund II will invest in 15-20 healthcare companies across therapeutics,...
00:10 , Nov 9, 2018 |  BioCentury  |  Finance

Biomatics’ next phase

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy. With Fund II, which...
13:02 , Nov 8, 2018 |  BC Extra  |  Financial News

Biomatics closes new fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase" ). Fund II will invest in 15-20 healthcare companies across therapeutics,...
19:08 , Jan 19, 2018 |  BioCentury  |  Finance

Incubating in China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing...
21:58 , Dec 15, 2017 |  BioCentury  |  Emerging Company Profile

CD38 hat trick

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates...
19:45 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
18:31 , Nov 16, 2017 |  BC Extra  |  Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
23:28 , Oct 31, 2017 |  BioCentury  |  Emerging Company Profile

Two faces of myeloid

Pionyr Immunotherapeutics Inc. has a pipeline of preclinical antibodies that could enable it to selectively deplete immunosuppressive myeloid cells from tumors without harming immune-stimulating myeloid cells. Myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived...
04:58 , Sep 22, 2017 |  BioCentury  |  Finance

Mining fungi

Through GV, LifeMine Therapeutics Inc. will have access to big data expertise as it builds out its fungal DNA mining capabilities. LifeMine raised $55 million in a series A round on Sept. 18 led by...
19:50 , Aug 4, 2017 |  BC Week In Review  |  Company News

Adimab grants Lilly rights to antibody discovery platform

Adimab LLC (Lebanon, N.H.) granted Eli Lilly and Co. (NYSE:LLY) exclusive rights to an antibody library and non-exclusive rights to Adimab’s antibody discovery platform in all therapeutic areas. Lilly will have an option to receive...